A Retrospective Analysis of Patients with Short Stature in Eastern China between 2013 and 2019
Table 2
Baseline clinical and biochemical characteristics of the subjects.
Year
All
2013
2014
2015
2016
2017
2018
2019
Number
1145
68
90
86
155
178
252
316
Sex (male %)
740 (64.63%)
45 (66.18%)
59 (65.56%)
56 (65.12%)
108 (69.68%)
111 (62.36%)
150 (59.52%)
211 (66.77%)
Age (years)
Bone age (years)
Height (cm)
Height SDS
Weight (kg)
BMI (kg/m2)
BMI SDS
-0.15 (-0.91-0.78)
-0.38 (-1.45-0.39)
-0.45 (-0.96-0.33)
-0.33 (-1.18-0.60)
-0.10 (-0.79-0.83)
-0.16 (-0.86-0.95)
0.03 (-0.62-0.97)
-0.18 (-0.91-0.73)
Peak GH (ng/ml)
7.44 (4.83-11.49)
7.03 (5.68-10.20)
8.92 (4.07-12.81)
9.25 (5.77-14.80)
7.53 (4.86-12.21)
8.02 (4.77-11.96)
6.58 (4.45-9.57)
7.72 (5.11-10.79)
IGF-1 (ng/ml)
197.00 (114.00-319.00)
157.50 (83.03-218.01)
189.00 (98.10-279.00)
168.00 (109.25-279.50)
173.00 (90.55-284.00)
200.50 (125.75-296.50)
220.00 (139.00-360.00)
212.00 (126.00-345.23)
IGF-1 SDS
-1.01 (-1.83--0.16)
-1.25 (-1.96--0.47)
-1.35 (-2.36--0.34)
-1.23 (-2.08--0.34)
-1.08 (-1.89--0.22)
-0.96 (-1.79--0.18)
-0.77 (-1.58-0.04)
-1.02 (-1.70--0.12)
IGFBP-3 (μg/ml)
Pubertal stage
In prepuberty (%)
658 (57.47%)
36 (52.94%)
53 (58.89%)
55 (63.95%)
88 (56.77%)
106 (59.55%)
134 (53.17%)
186 (58.86%)
In puberty (%)
487 (35.37%)
32 (47.06%)
37 (41.11%)
31 (36.05%)
67 (43.23%)
72 (40.45%)
118 (46.83%)
130 (41.14%)
Abbreviations: height SDS: height standard deviation scores; BMI SDS: body mass index standard deviation scores; IGF-1 SDS: insulin-like growth factor-1 standard deviation scores; IGFBP-3: insulin-like growth factor-binding protein-3; peak GH: peak growth hormone; normal distribution of data was presented as ; nonnormal distribution of data was presented as median (interquartile range) and categorical data using number (percentage).
